InvestorsHub Logo

TuesdaySmall

10/04/17 3:04 PM

#1503 RE: roctober #1502

Yes data should be published and released this month. >80%
New trials for both candidates are being started too. Insane the PPS sits where it does. I firmly believe it benefits Medivir and Tetralogic debt holders by keeping commons in the dark. Again just an opinion.

https://clinicaltrials.gov/ct2/show/NCT03180528?term=Remetinostat&rank=1